Compare · BBLG vs ZBH
BBLG vs ZBH
Side-by-side comparison of Bone Biologics Corp (BBLG) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $17.67B, about 7235.2x BBLG ($2.4M).
- Over the past year, BBLG is down 66.1% and ZBH is down 10.2% - ZBH leads by 55.9 points.
- ZBH has hit the wire 2 times in the past 4 weeks while BBLG has been quiet.
- ZBH has more recent analyst coverage (25 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- Zimmer Biomet Holdings Inc.
- Price
- $1.40+0.72%
- $91.33-1.18%
- Market cap
- $2.4M
- $17.67B
- 1M return
- +21.74%
- +4.25%
- 1Y return
- -66.13%
- -10.23%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 25
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest BBLG
- Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Bone Biologics Corp
- SEC Form 10-K filed by Bone Biologics Corp
- SEC Form 4 filed by Chief Financial Officer Walsh Deina H
- SEC Form 4 filed by Chief Executive Officer Frelick Jeff
- Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
- SEC Form 10-Q filed by Bone Biologics Corp
- SEC Form S-8 filed by Bone Biologics Corp
Latest ZBH
- Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
- Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
- SEC Form 4 filed by Noor Jehanzeb
- SEC Form 4 filed by Jafry Syed A.
- SEC Form 4 filed by Kolli Sreelakshmi
- SEC Form 4 filed by Shapiro Louis
- SEC Form 4 filed by Hilado Maria Teresa
- SEC Form 4 filed by Higgins Arthur J
- SEC Form 4 filed by Kurdikar Devdatt
- SEC Form 4 filed by Hagemann Robert